CTIS2024-517110-15-00进行中（未招募）1 期
Preoperative Lugol’s solution in Graves’ disease and toxic nodular goiter - LugolProtocol001
Karolinska University Hospital0 个研究点目标入组 182 人开始时间: 2024年8月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 182
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Pilot study: Hyperthyroidism due to toxic nodular goiter. Age 18-75 years. Main study: Hyperthyroidism due to toxic nodular goiter and Grave's disease accepted for thyroidectomy. Age 18-75 years.
排除标准
- •Unstable coronary artery disease Previous thyroid surgery Congestive heart failure Renal failure Liver failure Current infection Ongoing treatment with glucocorticoids Ongoing treatment with anticoagulants Thyroid associated ophtalmopathy CAS >2 Diabetes mellitus type1 Active cancer Severe psychiatric illness Amiodarone treatment Pregnancy Breast feeding Women with childbearing potential not using contraception Unability to comprehend the meaning of the study Iodine hypersensitivity
研究者
相似试验
招募中
3 期
Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular GoiterHyperthyroidismNCT04856488Jan Calissendorff182
进行中（未招募）
不适用
Preoperative Administration of Lugols Solution in Toxic Thyroid Diseases (TD): A Prospective StudyThyroid ToxicNCT06176976Aristotle University Of Thessaloniki50
进行中（未招募）
不适用
Adjuvant treatment of Graves´ ophthalmopathy with NSAID (aGO study) - aGO studyGraves´ophthalmopathyEUCTR2005-000832-26-SEDepartment of Endocrinology300
招募中
不适用
Resolution of Graves disease pathophysiology by flowcytometreyGraves diseaseJPRN-UMIN000017726niversity of Occupational and Environmental Health, Japan, First Department of Internal Medicine, School of Medicine100
进行中（未招募）
2 期
TOP GEAR: Trial of Preoperative Therapy for Gastric and Esophagogastric Junction AdenocarcinomaA randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancerResectable Gastric CancerCancer - StomachACTRN12609000035224Australasian Gastro-Intestinal Trials Group (AGITG)574